Zimmer Holdings, Inc. Form 10-Q Summary
Business Context and Reporting Period
The filing is for Zimmer Holdings, Inc. and its subsidiaries, not Zimmer Biomet Holdings, Inc. It covers the unaudited three months ended March 31, 2010, with comparisons to the same period in 2009. Zimmer designs, manufactures and markets orthopaedic reconstructive, dental, spine, trauma and related surgical products across the Americas, Europe and Asia Pacific.
Key Financial Metrics
| Metric | Q1 2010 | Q1 2009 | Change |
|---|---|---|---|
| Net sales | $1,062.8 million | $992.6 million | +7.1% |
| Gross profit | $794.4 million | $762.4 million | +4.2% |
| Gross margin | 74.7% | 76.8% | Down 210 bps |
| Operating profit | $294.1 million | $279.8 million | +5.1% |
| Operating margin | 27.7% | 28.2% | Down 50 bps |
| Net earnings | $205.4 million | $202.2 million | +1.6% |
| Diluted EPS | $1.01 | $0.91 | +11.0% |
| Cash flow from operations | $259.5 million | $184.6 million | +40.6% |
Sales growth was driven by 4 percentage points of volume and mix, a 1% pricing decline and a 4 percentage-point foreign-exchange benefit. Asia Pacific sales increased 21%, Europe increased 8% and the Americas increased 4%. Reconstructive implants, representing the largest product category, increased 7%; spine sales declined 7%.
Cash and cash equivalents were $821.2 million at March 31, 2010, compared with $691.7 million at December 31, 2009. Total current assets were $2,873.8 million versus current liabilities of $655.2 million. Long-term debt was $1,127.0 million, consisting of $998.8 million of senior notes and $128.2 million drawn under the senior credit facility; there was no short-term debt. The company reported $1,221.8 million of remaining availability under its $1,350 million revolving credit facility and an additional $83.9 million of uncommitted facilities.
Investing activities used $37.8 million, primarily for instruments and property, plant and equipment. Financing activities used $87.9 million, including $93.5 million for share repurchases. The company repurchased 1.5 million shares at an average price of $60.62, leaving $117.6 million authorized under its repurchase program.
Material Changes Versus the Prior Comparable Period
- Net sales rose 7%, but cost of products sold increased to 25.3% of sales from 23.2%, reflecting higher manufacturing costs per unit and less favorable foreign-exchange hedge results.
- Operating profit increased in dollars but operating margin declined to 27.7% from 28.2%.
- SG&A increased to $446.7 million from $423.7 million, while improving as a percentage of sales to 42.0% from 42.7%.
- Research and development expense declined slightly to $51.0 million; management expected full-year R&D spending to reach its 5% to 6% of sales target.
- Interest and other expense increased to $14.6 million from $3.7 million following the issuance of senior notes in November 2009.
- Operating cash flow improved substantially, aided by lower inventory levels and the absence of certain significant 2009 payments to healthcare professionals and institutions.
- Diluted EPS increased faster than net earnings because of share repurchases and the resulting lower share count.
Guidance, Outlook, Commentary and Risks
- Management expected global selling prices to decline approximately 1% to 2% in 2010 due to healthcare cost-containment efforts and pressure from hospitals and health systems.
- Foreign exchange was expected to provide approximately a 0% to 1% positive effect on full-year sales, with limited near-term net earnings impact because of hedging.
- Management cited improving global market conditions, stronger core reconstructive volume and mix, and a recovery in dental demand, while noting continued pressure in Europe.
- Capital spending on property, plant and equipment and instruments was expected to increase during the remainder of 2010 to support replacements and new product launches.
- The Durom Cup remains a significant product-liability matter. The company reported a $64.8 million liability for certain claims and a $29.0 million estimated liability for claims involving revisions occurring more than two years after the original surgery. It recorded $9.8 million of related standard product-liability expense in Q1 2010.
- The company remained subject to an SEC and Department of Justice investigation concerning potential Foreign Corrupt Practices Act matters and had voluntarily disclosed potential issues involving independent distributors in two South American countries.
- The Corporate Integrity Agreement with the U.S. Department of Health and Human Services runs through 2012; a material breach could result in exclusion from federal healthcare programs.
- Healthcare reform legislation included a 2.3% excise tax on a majority of U.S. medical-device sales beginning in 2013. Management stated that the ultimate impact remained uncertain and could materially affect results.
- The U.S. Spine reporting unit was tested for impairment because of continuing challenges. No Q1 2010 goodwill impairment charge was recorded, but the filing states that future impairment charges remain possible if estimated cash flows, margins or valuation assumptions deteriorate.
- Other risks include pricing pressure, reimbursement reductions, product liability, regulatory requirements, intellectual-property claims, currency fluctuations, competition, supplier concentration and execution of new-product and acquisition strategies.
Important Facts for Investors to Verify
- Confirm the issuer name and ticker because the supplied filing is for Zimmer Holdings, Inc., whereas the request metadata identifies Zimmer Biomet Holdings, Inc.
- Reconcile sales growth with the underlying volume/mix, pricing and foreign-exchange components, particularly the 2010 currency benefit.
- Monitor gross-margin pressure from manufacturing costs and foreign-exchange hedge results.
- Track Durom Cup claims, liability adequacy and future product-liability expense.
- Assess the effect of the 2013 medical-device excise tax and related healthcare reform regulations.
- Review the outcome of the FCPA investigation and compliance with the Corporate Integrity Agreement.
- Monitor U.S. Spine performance and the risk of future goodwill impairment.
- Verify the pace of share repurchases, remaining authorization and leverage under the revolving credit facility.